ArticleVeterinary world2025
Phenotype- and age-associated variations in non-specific agglutinins and complement components (C3 and C5a) in camels: Implications for transfusion compatibility and immune function.
Article in Veterinary world, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From Polyphenols to Prodrugs: Bridging the Blood-Brain Barrier with Nanomedicine and Neurotherapeutics.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aim: Blood transfusion in camels is hindered by poorly understood blood group systems, non-specific agglutinins, and a lack of standardized cross-matching protocols. Non-specific agglutinins, primarily immunoglobulin M (IgM), can lead to cross-reactivity, while complement components C3 and C5a impact transfusion outcomes and immune responses. This study aimed to evaluate age- and phenotype-related variations in non-specific agglutinins, C3, and C5a in camels to assess implications for transfusion compatibility and innate immunity. Materials and Methods: A total of 360 healthy male camels representing three phenotypes (black, yellow, and white) and four age groups (3-5, 5-8, 8-10, and >10 years) were sampled from slaughterhouses in Saudi Arabia. Serum agglutinin titers were determined using hemagglutination assays with heterologous red blood cells (RBCs). Heat inactivation (56°C, 30 min) and sheep RBC (SRBC) adsorption were applied to assess antibody specificity. C3 and C5a concentrations were quantified using an enzyme-linked immunosorbent assay. Statistical analyses employed analysis of variance with Tukey's Results: Yellow camels exhibited the highest agglutinin titers (up to 1338.4 ± 119.3 against black RBCs), with significant age-related increases. White camels showed the lowest reactivity but demonstrated marked age-related increase in C3 (3.252 ± 0.578 to 4.829 ± 0.983 μg/mL) and C5a (2.776-3.525 μg/mL). Black camels displayed moderate complement levels, peaking in older animals. Heat inactivation and SRBC adsorption substantially reduced titers across all phenotypes, confirming IgM dominance. Age-related increases in agglutinins and complement components indicated immune maturation or cumulative antigen exposure. Conclusion: Phenotypic and age-related immune differences significantly affect transfusion compatibility in camels. Yellow camels' high agglutinin activity poses greater transfusion risks, whereas white camels' lower reactivity and higher complement activity suggest potential as universal donors. Age-adjusted and phenotype-matched transfusion protocols, pre-transfusion heat inactivation, and monitoring C5a in older camels could enhance transfusion safety. This is the first comprehensive study linking camel phenotype and age to complement activation (C3 and C5a), providing a framework for improved transfusion practices and future genomic research into complement-related traits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.